We are comparing Cytokinetics Incorporated (NASDAQ:CYTK) and Intec Pharma Ltd. (NASDAQ:NTEC) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.
Table 1 highlights Cytokinetics Incorporated and Intec Pharma Ltd.’s top-line revenue, earnings per share and valuation.
Table 2 hightlights the return on equity, net margins and return on assets of the two companies.
The table delivered features the ratings and recommendations for Cytokinetics Incorporated and Intec Pharma Ltd.
Cytokinetics Incorporated’s upside potential is 77.51% at a $15 average price target.
Institutional Insider Ownership
The shares of both Cytokinetics Incorporated and Intec Pharma Ltd. are owned by institutional investors at 73.6% and 39.64% respectively. Cytokinetics Incorporated’s share held by insiders are 0.4%. Competitively, insiders own roughly 11.81% of Intec Pharma Ltd.’s